BioMarin Pharmaceutical Inc. (BMRN)
Oxford Ledge is still expanding full research coverage of BMRN. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
BioMarin is a rare disease biotechnology company with eight marketed therapies and a pipeline strengthened by recent acquisitions.
SEC filings
- 8-K Departure/election of directors or officers; Shareholder vote results 2026-06-04
- 10-Q Quarterly financial report (unaudited) 2026-05-05
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-04
- 8-K Entry into material agreement; Completion of acquisition or disposition; Creation of direct financial obligation; Regulation FD disclosure; Financial statements and exhibits 2026-04-27
- 8-K Other material event 2026-04-23
Source: SEC EDGAR.
Annual results
5 years of annual figures for BMRN, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $3.22B | $348.9M | $1.80 |
| 2024 | $2.85B | $426.9M | $2.21 |
| 2023 | $2.42B | $167.6M | $0.87 |
| 2022 | $2.10B | $141.6M | $0.75 |
| 2021 | $1.85B | -$64.1M | -$0.35 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for BMRN. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open BMRN in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.